Cui-Hong Han Selected Research

Roflumilast

1/2020

Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cui-Hong Han Research Topics

Disease

3	Hyperoxia 01/2020 - 01/2017
3	Lung Injury 01/2020 - 07/2017
2	Poisoning 01/2020 - 10/2016
2	Acute Lung Injury 01/2020 - 04/2016
1	Carbon Monoxide Poisoning (Poisoning, Carbon Monoxide) 01/2020
1	Edema (Dropsy) 01/2020
1	Inflammation (Inflammations) 01/2020
1	Neoplasms (Cancer) 06/2018
1	Decompression Sickness (Bends) 10/2016
1	Osteomyelitis 10/2016
1	Wounds and Injuries (Trauma) 10/2016
1	Soft Tissue Infections 10/2016
1	Air Embolism (Gas Embolism) 10/2016
1	Pathologic Processes 04/2016

Drug/Important Bio-Agent (IBA)

5	Oxygen (Dioxygen)IBA 01/2020 - 04/2016
1	RoflumilastIBA 01/2020
1	Carbon MonoxideIBA 01/2020
1	CytokinesIBA 01/2020
1	Neuroprotective AgentsIBA 01/2020
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 01/2020
1	VimentinIBA 06/2018
1	DesminIBA 06/2018
1	Angiotensin IIIBA 01/2017
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2017
1	Carbon DioxideIBA 10/2016
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2016

Therapy/Procedure

2	Decompression 10/2017 - 07/2017
1	Hyperbaric Oxygenation 01/2020
1	Therapeutics 01/2020
1	Liver Transplantation 10/2016